Sanofi, Regeneron widen antibody alliance

Sanofi (SANp) and Regeneron (REGN) have expanded their long‑standing antibody collaboration under a new agreement that could be worth up to $8 billion. The revised deal builds on the companies’ existing alliance in immunology and other therapeutic areas, adding new antibody assets and resetting the economic and governance terms of the partnership.

Under the expanded agreement, Sanofi will make a $1 billion upfront payment to Regeneron. In addition, Sanofi may pay up to $7 billion in development, regulatory and commercial milestone payments tied to the progress and performance of the new antibody programs, bringing the potential total value of the transaction to $8 billion.

Regeneron is contributing four fully human, long‑acting antibody programs to the collaboration. The lead asset is an IL‑13 antibody, referred to as REGN20423, which is already in clinical development for atopic dermatitis. This candidate is positioned as the most advanced of the new programs and anchors the expanded portfolio within the alliance.

Registrational studies for REGN20423 in atopic dermatitis are expected to begin in late 2027 or early 2028, marking the next major development milestone for the program. The remaining three antibody programs are at an earlier stage, either in preclinical testing or expected to enter clinical development in 2027, which could broaden the alliance pipeline over the medium term.

The expanded agreement also introduces a revised governance framework for how Sanofi and Regeneron will manage development and commercialization decisions across their shared portfolio. The updated structure is intended to clarify decision‑making rights and responsibilities between the partners as the number of co‑developed assets grows.

As part of the new arrangement, the companies stated that the agreement resolves prior litigation between them. The settlement of these disputes removes a source of uncertainty around the alliance and provides a clearer basis for advancing the newly added antibody programs alongside the existing partnered products.

By expanding their collaboration around long‑acting antibodies, Sanofi and Regeneron are reinforcing a shared focus on immunology and inflammatory diseases. The inclusion of multiple early‑ and mid‑stage programs creates a staggered development timeline, with REGN20423 as the near‑term clinical priority and three additional candidates following behind.

The combination of significant upfront and milestone economics, a broadened pipeline of fully human antibodies and clearer governance terms suggests that both companies are committing substantial resources to the next phase of their partnership. The resolution of earlier litigation may also streamline execution as the new programs progress toward key clinical and regulatory milestones over the coming years.